Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
1. A composition comprising a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3 residues 1-418.
2. The composition of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2, 3, 5, 6, 8, 9, 11, 12, 18, or 19.
3. The composition of claim 1 , wherein the composition further comprises an adjuvant.
4. The composition of claim 3 , wherein an adjuvant is selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 7 (TLR7) agonist, a toll-like receptor 8 (TLR8) agonist, a toll-like receptor 9 (TLR9) agonist, alum-containing adjuvant, monophosphoryl lipid A, and oil-in-water emulsion.
5. A pharmaceutical composition, comprising
(a) the composition of claim 1 ; and
(b) a pharmaceutically acceptable carrier.
6. The composition of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 3.
7. The composition of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3 residues 1-418.
8. The composition of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3.
9. The composition of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2 residues 1-438.
10. The composition of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.
11. The composition of claim 7 , wherein the composition further comprises an adjuvant.
12. The composition of claim 11 , wherein an adjuvant is selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 7 (TLR7) agonist, a toll-like receptor 8 (TLR8) agonist, a toll-like receptor 9 (TLR9) agonist, alum-containing adjuvant, monophosphoryl lipid A, and oil-in-water emulsion.
13. The composition of claim 9 , wherein the composition further comprises an adjuvant.
14. The composition of claim 13 , wherein an adjuvant is selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 7 (TLR7) agonist, a toll-like receptor 8 (TLR8) agonist, a toll-like receptor 9 (TLR9) agonist, alum-containing adjuvant, monophosphoryl lipid A, and oil-in-water emulsion.
15. A pharmaceutical composition, comprising
(a) the composition of claim 7 ; and
(b) a pharmaceutically acceptable carrier.
16. A pharmaceutical composition, comprising
(a) the composition of claim 9 ; and
(b) a pharmaceutically acceptable carrier.